News|Articles|November 16, 2026

Dexmedetomidine Receives FDA Approval for Acute Treatment for Agitation Associated With Schizophrenia

Listen
0:00 / 0:00

Key Takeaways

  • FDA approval establishes dexmedetomidine sublingual film as the first at-home option for acute agitation in adult schizophrenia, schizoaffective disorder, and bipolar I/II populations.
  • Agitation is characterized by excessive motor/verbal activity with tension and restlessness, affecting roughly 25%–40% of patients and creating substantial caregiver and system burden.
SHOW MORE

Dexmedetomidine is approved, becoming the first at-home treatment for schizophrenia-associated agitation.

Dexmedetomidine (Igalmi; Teva Pharmaceuticals) received FDA approval, making it the first at-home treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar 1 or 2 disorder in adults. The treatment, a sublingual film formulation, offers patients a new, simpler mode of treatment delivery during an episode.

“Innovation in neuroscience is about discovering new medicines and also about rethinking when, where, and how treatment can be delivered,” said Eric Hughes, MD, PhD, executive vice president, global R&D and chief medical officer at Teva. “The ability to treat agitation symptoms when they start gives patients and caregivers an important new way to manage these episodes.”

The approval fills a significant gap in treatment, allowing patients for the first time the ability to self-administer the therapy at home during an agitation episode, rather than waiting to seek medical care.

Agitation and Schizophrenia

Approximately 25% to 40% of patients with schizophrenia, schizoaffective disorder, or bipolar I or II disorder experience agitation—which is defined as excessive motor and verbal activity consistent with feelings of tension, restlessness, and increased activity. These episodes create significant challenges for patients, their families, and caregivers.

For patients with schizophrenia and related disorders, a rapid onset of action is a key consideration to avoid escalation of acute agitation. Statistics show that up to 21% of cases of acute agitation often lead to emergency department visits or hospitalization.

Dexmedetomidine and the SERENITY Trial

The phase 3 SERENITY At-Home Safety and Tolerability Trial (NCT05658510) met its primary end point of safety and tolerability. A total of 102 patients were treated with dexmedetomidine over a 12-week period. In the trial, investigators treated a total of 1160 agitation episodes.

The most common adverse events (incidence ≥ 5% and greater than placebo) were somnolence, dry mouth, dizziness, and oral paresthesia or oral hypoesthesia. No patients discontinued dexmedetomidine.

“For people living with schizophrenia, schizoaffective disorder, or bipolar disorder, agitation can be disruptive and challenging for themselves and for the caregivers who support them,” said Chris Fox, executive vice president, US commercial, and head of innovative franchise at Teva. “With the first FDA-approved, at-home treatment for agitation associated with these conditions, we have an opportunity to bring an important treatment option into a setting where patients often need it...”

REFERENCES
1. U.S. FDA approves IGALMI® as first at-home acute treatment for agitation associated with schizophrenia, schizoaffective disorder, or bipolar i or ii disorder in adults. Teva Pharmaceuticals. November 16, 2026. Accessed November 16, 2026.
2. The Spectrum of Agitation Associated with Schizophrenia and Bipolar Disorder. American Health and Drug Benefits. August 30, 2021. Accessed November 16, 2026. https://www.ahdbonline.com/articles/2007-the-spectrum-of-agitation-associated-with-schizophrenia-and-bipolar-disorder

Related to this article